bioRxiv Science⌕ Search

Biology subjects

Lomonossoff, G. P.

Publications and source records attributed to Lomonossoff, G. P..

5 recordsLinked to original sources

High-Resolution Structures of Tobacco Mosaic Virus Disks from Cryo-Electron Microscopy

Tobacco mosaic virus has been involved in many important developments in virology, structural biology, and biotechnology. Despite decades of study, several key aspects of the viral assembly mechanism remain unclear, particularly the structure of the coat protein disk that initiates virus assembly by interacting with the viral RNA. Here we report the first cryo-electron microscopy structures of the coat protein disk under conditions typically used for in vitro virus assembly. We identify 1-, 2-, and 3-layered disks, all of which differ significantly from previous structures obtained by X-ray crystallography. These new models lead to a revised viral assembly mechanism. We also compare coat proteins produced in bacteria and plants to better understand the effect of N-terminal acetylation.

biochemistry↗

Controlling heterologous protein synthesis through a plant RNA ThermoSwitch

Plants have evolved sophisticated mechanisms to adapt to temperature fluctuations, including transcriptional, post-transcriptional, and post-translational processes. Recent discoveries highlight RNA ThermoSwitches, cis-acting elements in several plant mRNAs that regulate protein synthesis based on temperature changes. These mechanisms, first identified in Arabidopsis thaliana, offer a promising tool for biotechnology by enabling temperature-sensitive control of protein expression. This study demonstrates, for the first time, the feasibility the application of plant RNA ThermoSwitches in Agrobacterium-mediated transient expression systems, presenting a novel method for controlled gene expression in plants. This system is particularly advantageous due to its homogeneous nature and independence from chemical inducers or suppressors.

plant biology↗

Unravelling the Maturation Pathway of a Eukaryotic Virus through Cryo-EM

The importance of virus maturation has been appreciated for nearly 70 years 1 as it provides models for large-scale protein reorganization resulting in functional activation as well as being a target for antiviral therapies 2. However, a detailed description of the pathway from the initial assembly product (procapsid) to the mature, infectious particle (virion) has been elusive. This is due to the "in cell" nature of the natural process, the 2- state behavior of maturation (no detectable intermediates) in some viruses in vitro 3 and heterogeneous populations of particle intermediates that are only partially matured in other systems 4. The non-enveloped, T=4, ssRNA-containing, Nudaurelia capensis omega virus (N{omega}V), is a highly accessible model system that exemplifies the maturation process of a eukaryotic virus. During maturation the particle shrinks in outer diameter from 482 [A] (pH 7.5) to 428 [A] (pH 5.0). It is possible to mimic the maturation process in vitro by lowering the pH of a population of procapsids produced in heterologous systems5. Indeed, by controlling the pH in vitro it is possible to produce homogenous populations of intermediate N{omega}V virus-like particles (VLPs) that occur too fleetingly to be observed in vivo 6. Here we report structural models, based on cryo-electron microscopy (cryo-EM), of five intermediates in the N{omega}V maturation process. The structures of the intermediate particles reveal unique, quaternary position-dependent trajectories and refolding of subunit N and C-terminal regions, including the formation of the autocatalytic cleavage site at N570. The detailed structures reported here, coupled with previously determined structures of the procapsids and mature particles, allows the maturation pathway to be described in detail for the first time for a eukaryotic virus.

biochemistry↗

Risk-free polio vaccine: Recombinant expression systems for production of stabilised virus-like particles

Polioviruses have caused crippling disease in humans for centuries, prior to the successful development of vaccines in the mid-1900s, which dramatically reduced disease prevalence. Continued use of these vaccines, however, threatens ultimate disease eradication and achievement of a polio-free world. Virus-like particles (VLPs) that lack a viral genome represent a safer potential vaccine, although they require particle stabilization. Using our previously established genetic techniques to stabilize the structural capsid proteins, we demonstrate production of poliovirus VLPs of all three serotypes, from four different recombinant expression systems. We compare the antigenicity, thermostability and immunogenicity of these stabilized VLPs against the current inactivated polio vaccine, demonstrating equivalent or superior immunogenicity. Structural analyses of these recombinant VLPs provide a rational understanding of the stabilizing mutations and the role of potential excipients. Collectively, we have established these poliovirus stabilized VLPs as viable next-generation vaccine candidates for the future.

microbiology↗

Assessments of hepatitis B virus-like particles and Crm197 as carrier proteins in melioidosis glycoconjugate vaccines

The Tier 1 select agent Burkholderia pseudomallei is the causative agent of melioidosis, a global pathogen and a major cause of pneumonia and sepsis for which no licensed vaccines currently exist. Previous work has shown the potential for Burkholderia capsular polysaccharide (CPS) to be used as a vaccine antigen but the T-cell independent nature of the immune response to this molecule requires the use of this polysaccharide as a glycoconjugate for vaccination. Recent studies have focussed on the use of Crm197 (a non-toxic mutant protein derived from diphtheria toxin) as the carrier but there are concerns regarding its potential to cause interference with other vaccines containing Crm197. Therefore research with alternative carrier proteins would be beneficial. In this study, CPS was isolated from the non-pathogenic B. thailandensis strain E555. This was chemically conjugated to Crm197, or Tandem Core virus-like particles (TCVLP) consisting of hepatitis B core protein, which is the first documented use of VLPs in melioidosis vaccine development. Analysis of CPS-specific IgG antibody titres showed that mice vaccinated with the Crm197 conjugate generated significantly higher titres than the mice that received TCVLP-CPS but both conjugate vaccines were able to protect mice against intraperitoneal B. pseudomallei strain K96243 challenges of multiple median lethal doses.

immunology↗